Member Exclusive

UniQure in gene therapy deal with BMS

UniQure NV has secured a gene therapy agreement with Bristol-Myers Squibb Company in cardiovascular disease, its first major commercial deal since winning regulatory approval in 2012 for Glybera, a gene therapy for lipoprotein lipase deficiency.

Go to the profile of Victoria English
Apr 06, 2015

Please sign in or register for FREE

No comments yet.